In recent years, the introduction of immune checkpoint inhibitors to the oncolytic pipeline has been a significant breakthrough in cancer treatment, but unfortunately some tumors respond only minimally. Besides CTLA-4, and since the approval of PD-1/PD-L1 inhibitors, only the anti-LAG3 strategy (relatlimab, Bristol Myers Squibb Co.) has been good enough to reach the market. In a session dealing with emerging checkpoints beyond PD-1, CTLA-4 and LAG3, Drew Rasco from the START Center for Cancer Care depicted a new player on the ground of immunotherapeutic options. Read More

Researchers from Mount Sinai School of Medicine have conducted preclinical studies on MS-8847... Read More

Transcode Therapeutics Inc. has reported successful treatment of preclinical melanoma... Read More

Splicebio S.L. has signed an exclusive collaboration and licensing agreement agreement with Spark... Read More

Shanghai Visonpharma Co. Ltd. has identified pyrimido-pyridazinone compounds acting as... Read More

Apogee Therapeutics Inc. recently presented preclinical data on its lead candidate, APG-777, a fully optimized and half-life extended antibody targeting IL-13 for the treatment of atopic dermatitis and asthma. Read More

Kyoto University has disclosed compounds and their nanoparticles acting as radiosensitizers for radiotherapy reported to be useful for the treatment of cancer. Read More

Arum Therapeutics Inc. has synthesized checkpoint kinase 2 (Chk2) inhibitors reported to be useful for the treatment of cancer. Read More

Researchers from Shanghai Jiao Tong University and affiliated organizations presented data from a study that aimed to identify new pathogenic genes for autosomal dominant hypotrichosis (hair loss). Read More

Dmtc Ltd. has divulged macrophage infectivity potentiator (Mip)-related protein (bacterial) inhibitors reported to be useful for the treatment of Q fever. Read More

Jazz Pharmaceuticals plc has described tricyclic phthalazines acting as son of sevenless homolog 1 (SOS1)/GTPase KRAS interaction inhibitors reported to be useful for the treatment of cancer. Read More

Cimeio Therapeutics Inc. has entered into a preclinical research collaboration with a researcher at the University of Pennsylvania (Penn) to research and evaluate a novel universal immunotherapy with potential to treat multiple blood and bone marrow cancers. Read More

New and updated preclinical data presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference in Boston, by: Astrazeneca, Boundless Bio, Corbus Pharmaceuticals, Fusion Pharmaceuticals, Phio Pharmaceuticals, Scorpion Therapeutics. Read More